- Status:
- Red
- Decision Date:
- February 2024
Comments
RED: Use in combination with azacitidine for the treatment of adults with newly diagnosed acute myeloid leukaemia with an isocitrate dehydrogenase-1 R132 mutation who are not eligible to receive standard induction chemotherapy. (Decision date - Sep 2023)
RED: for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments - as per NICE TA948. NHSE commissioned (Decision date - February 2024)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
